Antiparkinsonian drugs in the treatment of neuroleptic-induced extrapyramidal symptoms.
Most patients on neuroleptic therapy experience extrapyramidal symptoms in one form or another during treatment. While the risk of extrapyramidal symptoms appears diminished with the newer and "atypical" neuroleptics (for example, risperidone, remoxipride, clozapine), it is not eliminated. It is essential that the treating clinician monitor for such side effects since if they are left untreated they can be an ongoing source of discomfort to the patient and may affect compliance with therapy. Antiparkinsonian medication represents the mainstay of treatment for neuroleptic-induced extrapyramidal symptoms. Their clinical use is reviewed here with reference to mode of action, indications, choice, side-effects and precautions.
Bezchlibnyk-Butler
K Z
KZ
Clarke Institute of Psychiatry, Toronto, Ontario.
Remington
G J
GJ
D000978:Antiparkinson Agents / Q000009:adverse effects / Q000627:therapeutic use*; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001480:Basal Ganglia Diseases / Q000139:chemically induced* / Q000188:drug therapy; D004409:Dyskinesia, Drug-Induced / Q000188:drug therapy*; D006801:Humans; D010302:Parkinson Disease, Secondary / Q000139:chemically induced* / Q000188:drug therapy; D016896:Treatment Outcome
D000978:Antiparkinson Agents; D014150:Antipsychotic Agents